2020 Fiscal Year Final Research Report
Soluble urokinase receptor; a new diagnostic and therapeutic biomarker for nephrotic syndrome
Project/Area Number |
18K15988
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 53040:Nephrology-related
|
Research Institution | Kanazawa Medical University |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Keywords | 可溶性ウロキナーゼ受容体 / 原発性ネフローゼ症候群 / ポドサイト |
Outline of Final Research Achievements |
In this study, we observed that serum soluble urokinase receptor (s-suPAR) level changes during the first 2 months of immunosuppressive therapy, similar to those observed in the 2 months after the start of immunosuppressive therapy (s-suPAR2M), are useful indicators in primary nephrotic syndrome (NS) in differentially diagnosing refractory NS and predicting the time of 50 % serum creatinine (Cr) level increase, a surrogate marker for end-stage renal failure. Furthermore, the results of the time-dependent ROC analysis suggest that it is desirable to maintain s-suPAR2M levels at a maximum of approximately 3000 pg/mL to suppress the 50 % serum Cr level increase occurring 2 - 8 years later.
|
Free Research Field |
ネフローゼ症候群
|
Academic Significance and Societal Importance of the Research Achievements |
原発性NSの腎予後予測は治療開始後6か月時点における治療反応性で判定しているのが現状であり、初期治療段階における非侵襲的腎予後予測マーカーは確立していない。本研究結果は、血清suPARを用いて初期治療段階でNS治療反応性が悪く末期腎不全に至る可能性の高い患者を鑑別可能であることを示している。血清suPARを指標としてハイリスク患者を早期診断することで適切な治療介入を迅速に開始することが可能となり、腎予後の改善が期待できる。
|